内源性β3肾上腺素能受体激活通过PI3K/Akt信号通路减轻脓毒症诱导的心肌细胞凋亡
研究在盲肠结扎穿孔(CLP)脓毒症大鼠和脂多糖(LPS)处理的心肌细胞中观察β3肾上腺素能受体(β3-AR)激活对心肌细胞凋亡与心功能的影响。β3-AR在成年大鼠心室肌细胞(ARVM)和H9c2细胞中均有表达,LPS处理ARVM及CLP大鼠心脏中β3-AR表达上调。β3-AR激动剂BRL37344预处理抑制LPS诱导的ARVM凋亡及caspase-3、-8、-9活化;在H9c2细胞中减少凋亡并升高PI3K、p-Akt Ser473和p-eNOS Ser1177蛋白水平,而PI3K抑制剂LY294002可消除上述抑制caspase活化的效应。β3-AR拮抗剂SR59230A(5 mg/kg)降低CLP脓毒症大鼠左心室压力最大上升速率(+dP/dt),增加心肌凋亡、降低p-Akt Ser473与Bcl-2,并升高线粒体Bax、胞质细胞色素c、cleaved caspase-9和cleaved caspase-3水平。作者据此提出内源性β3-AR激活经PI3K/Akt通路减轻脓毒症心肌凋亡并维持内源性心肌收缩功能。
要点
- β3-AR在成年大鼠心室肌细胞(ARVM)和H9c2细胞中均有表达,LPS处理ARVM及CLP大鼠心脏中β3-AR表达上调。
- β3-AR激动剂BRL37344预处理抑制LPS诱导的ARVM凋亡及caspase-3、-8、-9活化。
- BRL37344减少LPS处理H9c2细胞凋亡并升高PI3K、p-Akt Ser473和p-eNOS Ser1177蛋白水平;PI3K抑制剂LY294002消除其对caspase-3、-8、-9活化的抑制效应。
- β3-AR拮抗剂SR59230A(5 mg/kg)显著降低CLP脓毒症大鼠左心室+ dP/dt,并增加心肌凋亡、降低p-Akt Ser473与Bcl-2、升高线粒体Bax、胞质细胞色素c、cleaved caspase-9和cleaved caspase-3。
- 作者认为内源性β3-AR激活通过PI3K/Akt信号通路减轻脓毒症诱导的心肌细胞凋亡并维持内源性心肌收缩功能。
适用人群与场景
- 盲肠结扎穿孔(CLP)脓毒症大鼠模型。
- 脂多糖(LPS)处理的成年大鼠心室肌细胞(ARVM)和H9c2细胞。
处置流程与药物剂量
- β3-AR激动剂BRL37344用于预处理LPS处理的ARVM和H9c2细胞。
- PI3K抑制剂LY294002用于H9c2细胞以阻断PI3K。
- β3-AR拮抗剂SR59230A按5 mg/kg给药用于CLP诱导的脓毒症大鼠。
研究设计与关键结果
- β3-AR在ARVM和H9c2细胞中均有表达,LPS处理ARVM及CLP大鼠心脏中β3-AR表达上调。
- BRL37344预处理抑制LPS诱导的ARVM凋亡及caspase-3、-8、-9活化。
- BRL37344减少LPS处理H9c2细胞凋亡并升高PI3K、p-Akt Ser473和p-eNOS Ser1177蛋白水平。
- LY294002消除BRL37344对LPS诱导的H9c2细胞caspase-3、-8、-9活化的抑制效应。
- SR59230A(5 mg/kg)显著降低CLP脓毒症大鼠左心室+ dP/dt,增加心肌凋亡、降低p-Akt Ser473与Bcl-2,升高线粒体Bax、胞质细胞色素c、cleaved caspase-9和cleaved caspase-3。
证据类型、等级与局限
- 证据类型:动物实验与细胞实验(CLP大鼠模型及LPS处理的心肌细胞)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为内源性β3-AR激活通过PI3K/Akt信号通路减轻脓毒症诱导的心肌细胞凋亡并维持内源性心肌收缩功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
β 3 -adrenergic receptor (β 3 -AR) has been proposed as a new therapy for several myocardial diseases. However, the effect of β 3 -AR activation on sepsis-induced myocardial apoptosis is unclear. Here, we investigated the effect of β 3 -AR activation on the cardiomyocyte apoptosis and cardiac dysfunction in cecal ligation and puncture (CLP)-operated rats and lipopolysaccharide (LPS)-treated cardiomyocytes. We found that β 3 -AR existed both in adult rat ventricular myocytes (ARVMs) and H9c2 cells. The expression of β 3 -AR was upregulated in LPS-treated ARVMs and the heart of CLP rats. Pretreatment with β 3 -AR agonist, BRL37344, inhibited LPS-induced cardiomyocyte apoptosis and caspase-3, -8, and -9 activation in ARVMs. BRL37344 also reduced apoptosis and increased the protein levels of PI3K, p-Akt Ser473 and p-eNOS Ser1177 in LPS-treated H9c2 cells. Inhibition of PI3K using LY294002 abolished the inhibitory effect of BRL37344 on LPS-induced caspase-3, -8, and -9 activation in H9c2 cells. Furthermore, administration of β 3 -AR antagonist, SR59230A (5 mg/kg), significantly decreased the maximum rate of left ventricular pressure rise (+dP/dt) in CLP-induced septic rats. SR59230A not only increased myocardial apoptosis, reduced p-Akt Ser473 and Bcl-2 contents, but also increased mitochondrial Bax, cytoplasm cytochrome c, cleaved caspase-9, and cleaved caspase-3 levels of the myocardium in septic rats. These results suggest that endogenous β 3 -AR activation alleviates sepsis-induced cardiomyocyte apoptosis via PI3K/Akt signaling pathway and maintains intrinsic myocardial systolic function in sepsis.
参考来源
- Xing Y, Tian T, Zhang X, et al. ENDOGENOUS β 3 -ADRENERGIC RECEPTOR ACTIVATION ALLEVIATES SEPSIS-INDUCED CARDIOMYOCYTE APOPTOSIS VIA PI3K/AKT SIGNALING PATHWAY. Shock. 2024. PMID: 38662592. doi:10.1097/SHK.0000000000002354
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。